A NEW anti-epileptic medication,
VIMPAT (lacosamide), has been
approved for use on the
Pharmaceutical Benefits Sheme
from 01 May.
VIMPAT has been approved for
use in people aged over 16 years
who suffer uncontrolled partial
onset epilepsy (focal epilepsy) and
have already tried and failed a
number of first and second-line
anti-epileptic drugs.
MEANWHILE the first continuous
erythropoietin receptor activator
that offers once monthly
maintenance dosing for patients
with anaemia associated with
chronic kidney disease, MIRCERA
(methoxy polyethylene glycolepoetin
beta, is now available to
patients on the PBS.
Other benefits of MIRCERA
include no refrigeration required,
with the once per month injections
also offering a reduction of up to
80% in nursing time spent
managing renal anaemia to
improve health system efficiency.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.